Dana-Farber Cancer Institute
NEWS
ZN-c3 is a WEE1 inhibitor that could be used as monotherapy for uterine serous carcinoma and solid tumors, as well as combination therapy for ovarian cancer, alongside chemotherapy.
SpringWorks has announced a research collaboration with the Dana-Farber Cancer Institute to advance its therapy development efforts for multiple myeloma and related diseases.
The research collaboration will see the development of bispecific antibodies and CAR-T cell products.
The duo launch Riverway Discoveries to drive the development and commercialization of new cancer therapeutics faster into patient’s hands.
It will combine MPM’s venture capital investment fundraising with Dana-Farber’s philanthropic fundraising for cancer research.
It was a very busy week for clinical trial news. Here’s a look.
The study was in 55 patients who had an average of three previous treatment regimens. The results are promising enough that a Phase III trial is planned.
A new blood test in development from GRAIL, Inc. and studied by investigators at the Dana-Farber Cancer Institute has the ability to accurately screen for numerous types of cancer.
Cancer cells appear to adapt to treatment with checkpoint blocker drugs by altering a metabolic process, leading to shorter survival for patients
JOBS
IN THE PRESS